Kintor Pharmaceutical Limited (HKG: 9939) entered into a strategic cooperation agreement with Zhejiang Fonow Medicine Co., Ltd. to accelerate R&D, registration, and production of functional special-purpose cosmetics containing KT-939 raw material. Under terms, Kintor supplies the active pharmaceutical ingredient and grants Fonow exclusive China rights to develop, manufacture, and market whitening and spot-removing products, complementing Fonow’s core Folimei Cream franchise in the melasma treatment market.
Revenue Model: Kintor receives API supply fees + milestone/royalty payments on finished product sales; Fonow bears development and commercialization costs
Regulatory Pathway:Special-purpose cosmetics require NMPA registration (12–18 month timeline); “whitening” claims subject to strict efficacy and safety documentation
Forward‑Looking Statements This brief contains forward‑looking statements regarding partnership execution, cosmetic product registration timelines, and market penetration for KT-939-based formulations. Actual results may differ due to NMPA regulatory requirements, competitive dynamics in the whitening cosmetics segment, and consumer adoption patterns.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
